Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat

References

• Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. (2007). Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 127:1419–1429.
   PubMed Web of Science ®Google Scholar
• Baririan N, Desager JP, Petit M, Horsmans Y. (2006). CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination. J Pharm Biomed Anal 40:211–214.
   PubMed Web of Science ®Google Scholar
• Baumgart A, Schmidt M, Schmitz HJ, Schrenk D. (2005). Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes. Biochem Pharmacol 69:657–667.
   PubMed Web of Science ®Google Scholar
• Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, Béraud E. (2001). Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 166:936–944.
   PubMed Web of Science ®Google Scholar
• Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG. (2005). Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 67:1369–1381.
   PubMed Web of Science ®Google Scholar
• Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E. (2001). Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98:13942–13947.
   PubMed Web of Science ®Google Scholar
• Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. (2006). Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103:17414–17419.
   PubMed Web of Science ®Google Scholar
• Caffieri S. (2002). Furocoumarin photolysis: chemical and biological aspects. Photochem Photobiol Sci 1:149–157.
   PubMed Web of Science ®Google Scholar
• Cahalan MD, Chandy KG. (2009). The functional network of ion channels in T lymphocytes. Immunol Rev 231:59–87.
   PubMed Web of Science ®Google Scholar
• Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. (2004). K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci 25:280–289.
   PubMed Web of Science ®Google Scholar
• da Silva VB, Kawano DF, Carvalho I, da Conceição EC, de Freitas O, da Silva CH. (2009). Psoralen and bergapten: in silico metabolism and toxicophoric analysis of drugs used to treat vitiligo. J Pharm Pharm Sci 12:378–387.
   Google Scholar
• Daniel WA, Syrek M, Haduch A. (2002). The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics. Eur Neuropsychopharmacol 12:371–377.
   PubMed Web of Science ®Google Scholar
• Elsherbiny ME, El-Kadi AO, Brocks DR. (2008). The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci 11:147–159.
   PubMed Web of Science ®Google Scholar
• Erickson DA, Hollfelder S, Tenge J, Gohdes M, Burkhardt JJ, Krieter PA. (2007). In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos 35:2232–2241.
   PubMed Web of Science ®Google Scholar
• Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Karmilowicz MJ, Auperin DD, Chandy KG. (1994). Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45:1227–1234.
   PubMed Web of Science ®Google Scholar
• Hill JR. (2003). In vitro drug metabolism using liver microsomes. Current Protocols in Pharmacology. New York: Wiley Inter-science.
   Google Scholar
• John BA, Chasseaud LF, Wood SG, Forlot P. (1992). Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog. Xenobiotica 22:1339–1351.
   PubMed Web of Science ®Google Scholar
• Koenigs LL, Trager WF. (1998). Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry 37:13184–13193.
   PubMed Web of Science ®Google Scholar
• Koenigs LL, Trager WF. (1998). Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 37:10047–10061.
   PubMed Web of Science ®Google Scholar
• Logsdon NJ, Kang J, Togo JA, Christian EP, Aiyar J. (1997). A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J Biol Chem 272:32723–32726.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894.
   PubMed Web of Science ®Google Scholar
• Mays DC, Rogers SL, Guiler RC, Sharp DE, Hecht SG, Staubus AE, Gerber N. (1986). Disposition of 8-methoxypsoralen in the rat: methodology for measurement, dose-dependent pharmacokinetics, tissue distribution and identification of metabolites. J Pharmacol Exp Ther 236:364–373.
   PubMedGoogle Scholar
• Monostory K, Tamási V, Vereczkey L, Perjési P. (2003). A study on CYP1A inhibitory action of E-2-(4′-methoxybenzylidene)-1-benzosuberone and some related chalcones and cyclic chalcone analogues. Toxicology 184:203–210.
   PubMed Web of Science ®Google Scholar
• Pereira LE, Villinger F, Wulff H, Sankaranarayanan A, Raman G, Ansari AA. (2007). Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood) 232:1338–1354.
   PubMed Web of Science ®Google Scholar
• Ropp S, Guy J, Berl V, Bischoff P, Lepoittevin JP. (2004). Synthesis and photocytotoxic activity of new alpha-methylene-gamma-butyrolactone-psoralen heterodimers. Bioorg Med Chem 12:3619–3625.
   PubMed Web of Science ®Google Scholar
• Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H. (2005). Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 68:1254–1270.
   PubMed Web of Science ®Google Scholar
• Wulff H, Castle NA, Pardo LA. (2009). Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8:982–1001.
   PubMed Web of Science ®Google Scholar
• Zimin PI, Garic B, Bodendiek SB, Mahieux C, Wulff H, Zhorov BS. (2010). Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Mol Pharmacol 78:588–599.
   Google Scholar